BOM:500087

Cipla's Goa, India Facility Receives VAI Status from US FDA

Cipla (NSE:CIPLA, BOM:500087) said the U.S. Food and Drug Administration classified an inspection of its manufacturing facility in Verna, Goa, as Voluntary Action Indicated (VAI), according to a Thursday filing on Indian exchanges.A VAI classification indicates that "objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action," according to the inspection classification available on U.S. FDA website.The inspection, which included a routine inspection of current Good Manufacturing Practices and a pre-approval inspection, was conducted between April 6 and 17, the filing said.Shares of the company rose nearly 1% in recent trade.

Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349

Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180

Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450

JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546

Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404

Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455

Jefferies Adjusts Cipla's Price Target to INR1,120 From INR1,170, Keeps at Underperform

Cipla (NSE:CIPLA, BOM:500087) has an average rating of overweight and mean price target of 1,435.78 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

ICICI Securities Upgrades Cipla to Buy from Add; Price Target is INR1,550

Indian Equities Extend Losses on Thursday as Banking Sell-Off, Crude Oil Surge Weigh

Indian benchmark indices declined sharply on Thursday as selling in banking stocks and higher crude oil prices dragged the market lower.The BSE Sensex fell 852.49 points, or 1.1%, to close at 77,664.00, while the NSE Nifty 50 dropped 205.05 points, or 0.8%, to settle at 24,173.05.Sentiment remained weak amid rising tensions in the Middle East and uncertainty around U.S.-Iran talks. Reports of fresh maritime incidents and lack of clarity on the next round of negotiations kept investors cautious despite an extension of the ceasefire.Union Bank of India (NSE:UNIONBANK, BOM:532477) declined over 7% after reporting a rise in fiscal Q4 profit to 55.0 billion rupees from 50.1 billion rupees a year earlier.Cipla (NSE:CIPLA, BOM:500087) gained nearly 6% after its subsidiary received U.S. FDA approval for Albuterol Sulfate Inhalation Aerosol. The product is expected to be launched in the first half of fiscal 2027.

Cipla Arm Gets US FDA's Final Nod for Albuterol Sulfate Inhalation Aerosol; Shares Up 3%

Cipla USA Inc., a wholly-owned subsidiary of Cipla (NSE:CIPLA, BOM:500087), has received final approval from the U.S. Food and Drug Administration for its Albuterol Sulfate Inhalation Aerosol, according to a Thursday filing to the Indian stock exchanges.The drug is a generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.Albuterol Sulfate Inhalation Aerosol is used to treat or prevent bronchospasm with reversible obstructive airway disease, and to prevent exercise-induced bronchospasm.The product is expected to be launched in the first half of the financial year 2026-27 in the US.According to IQVIA estimates, the total US albuterol market is valued at around $1.5 billion.The company's shares were up over 3% in recent trade.